MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) — via IBN — Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis’ clinical trials.
“We are thrilled to welcome Matthew Peterson to our team,” said Cheng Fang, Ph.D., Senior Vice President, Research and Development, at Annovis. “Dr. Peterson brings an impressive track record in clinical research and a passion for improving patient outcomes, joining us at a crucial moment as we are approaching initiation of pivotal Phase 3 studies.”
Dr. Peterson joins Annovis with experience in both academic research and the life sciences industry. Most recently, he served as Senior Clinical Research Science Manager at Axogen, where he focused on therapies for peripheral nerve repair and regeneration. His previous roles include Clinical Research Scientist Contractor at Ethicon and Senior Clinical Project Manager at Exactech, along with a decade-long tenure at the Department of Veterans Affairs (VA). During his time at the VA, Dr. Peterson led studies on pressure ulcer prevention, fall risk assessment, and interventions to improve the quality of life for veterans with spinal cord injuries and other conditions. Dr. Peterson holds a Ph.D. in Biomedical Engineering from the University of Florida, where he specialized in developing technologies aimed at reducing clinical complications for vulnerable patient populations. He has authored numerous peer-reviewed publications and served as a principal investigator on studies funded by organizations including the Department of Defense and the VA.
“I am excited to join Annovis and to work alongside such a dedicated team at this pivotal moment for the company,” said Dr. Peterson. “I look forward to contributing to the clinical development of buntanetap and supporting the company’s goal of bringing transformative therapies to patients affected by neurodegenerative diseases.”
About Annovis Bio
Headquartered in Malvern, Pennsylvania, Annovis Bio is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.annovisbio.com/email-alerts. Additionally, we invite you to explore our updated investor website, which provides comprehensive access to company news, financial reports, and other key information.
Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company’s plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company’s clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company’s periodic filings with the SEC, including those listed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
www.annovisbio.com/investors-relations
IR@annovisbio.com
Bay Street News